• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in treatment of gastric cancer with peritoneal carcinomatosis

    2017-04-28 03:16:12LynneEllisonYangaoManAlexanderStojadinovicHongwuXinItzhakAvital
    Chinese Journal of Cancer Research 2017年1期

    Lynne M. Ellison, Yangao Man, Alexander Stojadinovic, Hongwu Xin, Itzhak Avital

    1Bon Secours Cancer Institute, Bon Secours Health System, Richmond, VA 23226, USA;2Laboratory of Oncology, the First People’s Hospital of Jingzhou City, the First Hospital and Clinical Medical School of Yangtze University, Jingzhou 434008, China;3Laboratory of Oncology, Center for Molecular Medicine, Medical School, Yangtze University, Jingzhou 434023, China

    Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in treatment of gastric cancer with peritoneal carcinomatosis

    Lynne M. Ellison1, Yangao Man1, Alexander Stojadinovic1, Hongwu Xin2,3, Itzhak Avital1

    1Bon Secours Cancer Institute, Bon Secours Health System, Richmond, VA 23226, USA;2Laboratory of Oncology, the First People’s Hospital of Jingzhou City, the First Hospital and Clinical Medical School of Yangtze University, Jingzhou 434008, China;3Laboratory of Oncology, Center for Molecular Medicine, Medical School, Yangtze University, Jingzhou 434023, China

    Although gastric cancer with peritoneal carcinomatosis is associated with poor prognosis and is generally treated with palliative systemic therapy, recent studies have shown that cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) may prove to be an efficacious treatment option. In addition to reviewing the natural history of gastric cancer with peritoneal carcinomatosis, this mini-review examines literature on the efficacy of CRS and HIPEC as compared to chemotherapy and surgical options. Both randomized and nonrandomized studies were summarized with the emphasis focused on overall survival. In summary, CRS and HIPEC are indeed a promising treatment option for gastric cancer with peritoneal carcinomatosis and large randomized clinical trials are warranted.

    Cytoreductive surgery; hyperthermic intraperitoneal chemotherapy; peritoneal carcinomatosis

    View this article at: http://dx.doi.org/10.21147/j.issn.1000-9604.2017.01.10

    Introduction

    Although the incidence of gastric cancer has decreased over the years, it is the fifth leading cause of cancer worldwide after lung, breast, colorectal and prostate cancers and it is the third most common cause of cancer deaths worldwide after lung and liver cancers (1,2). Gastric cancer accounted for 10% of the total cancer-related deaths and 8% of the total cancer cases in 2008 with over 70% of new cases and deaths occurring in developing countries (3). Asia and Eastern Europe have the highest rates of disease (4). The 5-year overall survival (OS) for gastric cancer is approximately 15%–20% and the survival rate drops steeply as the staging progresses. When localized to the stomach the 5-year OS is approximately 55%, but by stage IV the 5-year OS decreases to 4%.

    Peritoneal carcinomatosis arising from gastric cancer is generally associated with poor prognosis. Risk factors found to be significantly associated with peritoneal carcinomatosis in literature include tumor stage T3/T4 (5-9), age ≤60 years (9), histological type (including signetring cell features) (6,10), nodal invasion (7,8), vascular invasion (6), ascites (5), liver metastasis (5), and female gender (10). The median survival rates for peritoneal carcinomatosis range from 1 to 9 months with no survival at the 5th year (11).

    Recently, Thomassenet al. (10) did a population-based study to investigate the morbidity and mortality among patients with peritoneal carcinomatosis of gastric origin and found the median survival of patients with peritonealmetastasis to be 4 months as compared to 14 months in patients without metastasis. Out of the 5,220 patients studied, 39% of them presented with metastatic disease and 35% of them had peritoneal carcinomatosis. Similarly, Sadeghiet al. (5) found the OS was 3.1 months and over half were diagnosed with peritoneal carcinomatosis at the time of primary gastric cancer diagnosis in their prospective trial.

    Surgery along with adjuvant chemotherapy or chemoradiation has been the mainstay treatment of nonmetastatic gastric cancer over the years with palliative systemic chemotherapy being the standard of care in advanced or recurrent gastric cancer. Within the last three decades, there has been an increasing interest in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in treating advanced gastric carcinoma with peritoneal carcinomatosis with the goal of killing any residual microscopic disease that may be present after completely removing the macroscopic disease. The intent of this article is to review literature dealing with treatments for gastric cancer with peritoneal carcinomatosis including chemotherapy, surgery, and HIPEC.

    Current approaches for gastric cancer with peritoneal carcinomatosis

    Chemotherapy and surgery

    Palliative chemotherapy is the standard of care in advanced or recurrent gastric cancer. Wagneret al. (12) published a systematic review in 2010 that evaluated the effect of chemotherapy in patients with advanced gastric cancer as compared to best supportive care. They found a 6.7 month improvement in median survival (from 4.3 to 11.0 months) in the chemotherapy group when compared with the best supportive care (Table 1). In 2013, Global Advanced/ Adjuvant Stomach Tumor Research International Collaboration (GASTRIC) (13) did a meta-analysis on the efficacy of chemotherapy on OS and progression-free survival (PFS) in advanced/recurrent gastric cancer. When comparing the experimental chemotherapy arms with the corresponding control arms, the hazard ratio was 0.88 and 0.81 in regards to OS and PFS. These hazard ratios equated to a median OS difference of 3 weeks (37.6 and 34.4 median in weeks) and a PFS difference of 4 weeks (20.4 and 16.4 median in weeks). The GASTRIC study exemplified how chemotherapy in addition to standard regimens has yielded minimal improvement in OS and progression-free intervals with no certain chemotherapy regimen emerging as a better standard (13). Although chemotherapy is the mainstay treatment for advanced gastric cancer, there does not seem to be any set consensus on the overall efficacy of treatment.

    The outcome of surgical intervention is often predicated by the progression of gastric cancer. Hiokiet al. (14) found that gastrectomy increased survival in patients with metastasis to adjacent peritoneum (P1) and few scattered metastasis to adjacent peritoneum (P2) but not in patients with numerous distant peritoneal metastasis (P3). They found that the OS in P1, P2 and P3 groups was 18 months, 15 months and 9 months, respectively. Furthermore, the 1-year survival was found to be 64.7%, 69.2% and 35.2%, respectively. However, Kimet al. (9) found that there was no significant trend of improved survival after surgical management of HIPEC.

    Currently, there are no large randomized studies examining the efficacy of surgery and systemic therapy versus systemic therapy alone in patients with advanced metastatic gastric cancer. The GYMSSA trial will be conducted by the National Cancer Institute and will compare gastrectomy, metastectomy plus systemic therapy versus systemic chemotherapy alone in metastatic gastric cancer patients (15). This trial will highlight whether or not there is a benefit to aggressive surgical intervention in addition to the current chemotherapeutic standard of care.

    CRS plus HIPEC versus chemotherapy

    Hultmanet al. (16) compared systemic chemotherapy followed by CRS and HIPEC with systemic chemotherapy only in patients with peritoneal carcinomatosis from gastriccancer and found the mean OS in the experimental group was 20.5 months as compared to 11.1 months in the control group (Table 2).

    Table 1 Comparison of median survival times of chemotherapy versus surgery

    Table 2 Comparison of mean and median survival of CRS+ HIPEC+EPIC versus chemotherapy groups (Ref 16)

    CRS plus HIPEC versus surgery

    It has been shown that if intraperitoneal free cancer cells are present after curative surgery in advanced gastric patients, the 5-year survival rate is only 15.4%, as compared to 49.4% if no intraperitoneal cancer cells are found (17). Furthermore, Kuramotoet al. (18) found that extensive intraoperative peritoneal lavage followed by intraperitoneal chemotherapy (EIPL-IPC) significantly increased the 5-year survival rate on patients with intraperitoneal free cancer cells without overt peritoneal metastasis (CY+/P) as compared to surgery plus IPC and surgery alone groups. The 5-year survival rate was 43.8%, 4.6% and 0% in the EIPL-IPC, IPC and surgery alone groups, respectively (18). The goal of HIPEC in killing off microscopic tumor cells that may be present after CRS is a promising treatment modality for gastric cancer with peritoneal carcinomatosis.

    There are a limited amount of randomized trials on CRS and HIPEC in gastric cancer with peritoneal carcinomatosis. Yanget al. (19) completed a randomized phase III study and found the median survival for the CRS+HIPEC group was 11.0 months as compared to 6.5 months in the CRS alone group. Yonemuraet al. (20) did a prospective randomized study on 139 patients with advanced gastric cancer who were treated with either chemohyperthermic peritoneal perfusion (CHPP) and surgery, chemonormothermic peritoneal perfusion (CNPP) and surgery, or surgery alone. They found that the 5-year OS rates for CHPP, CNPP and surgery alone groups were 61%, 43% and 42%, respectively. Fujimuraet al. (21) did a randomized study that showed improved survival in patients receiving continuous hyperthermic peritoneal perfusion or continuous normothermic peritoneal perfusion as compared to the gastric surgery without perfusion group. Furthermore, the significant differences in the survival curves showed that peritoneal perfusion, whether hyperthermic or normothermic, is an effective procedure for preventing peritoneal recurrence. Yuet al. (22) did a prospective randomized trial which showed that gastric resection plus early postoperative intraperitoneal chemotherapy improved the 5-year OS compared with surgery only in patients with stage IV gastric cancer (28% and 5%, respectively).

    There are many nonrandomized studies dealing with CRS and HIPEC. Fujimotoet al. (23) did a nonrandomized study and found increased survival rate for gastric cancer patients with peritoneal carcinomatosis receiving intraperitoneal hyperthermic chemoperfusion and aggressive surgery as compared to surgery alone. Hiroseet al. (24) did a nonrandomized study to investigate the efficacy of continuous hyperthermic peritoneal perfusion with surgery as compared to surgery alone by a multivariate regression analysis. The continuous hyperthermic peritoneal perfusion group had higher median survival time and 1-year survival rate as compared to the control group: 11 months and 44.4% versus 6 months and 15.8%, respectively. Similarly, Yonemuraet al. (25) found the median survival of 11.5 months in the patients who received cytoreduction and intraperitoneal hyperthermic chemotherapy (IPHC). Glehenet al. (26) found the median survival of patients receiving CRS followed by IPC to be 10.3 months with the median survival increasing to 21.3 months when a completeness of cytoreduction (CCR) score of CCR-0 or CCR-1 was obtained (Table 3).

    Complete versus incomplete cytoreduction

    While CRS and HIPEC are promising treatment modalities for gastric cancer with peritoneal carcino-matosis, the success of the treatment is largely dependent on the resection status. Hallet al. (27) evaluated CRS and IPHC with peritoneal carcinomatosis from gastric cancer. The study investigated the outcomes of patients who underwent gastric resection with CRS followed by IPHC with mitomycin C, while the control group underwent radical gastrectomy without extended nodal resection. The OS was similar between the experimental and control groups (7.8 months and 8.0 months, respectively), and the OS time in the IPHC group was dependent on resection status. Within the IPHC group, a median survival time was 11.2 months if R0/R1 resection was completed as compared to 3.3 months if R2 resection was completed. Yonemuraet al. (25) completed a retrospective study on 107 patients with peritoneal dissemination of gastric cancer who had intraoperative CHPP after CRS to see whether or not CCR or peritonectomy had an effect on OS and they found that the overall median survival was 11.5 months. The median survival was 15.5 months and 7.9 months in the complete and incomplete cytoreduction groups, respectively. The 5-year survival rate was 6.7% overall, and in the peritonectomy group, it was 27%. Scaringiet al. (28) found a 23.4 month median survival in patients without demonstrable peritoneal carcinomtosis who received CRS+HIPEC while the peritoneal carcinomatosis group had a median survival of 6.6 months. The median survival was 15 months when curative CRS was performed versus the median survival of 3.9 months in the palliative group. Similarly, Yanget al. (29) found that the median survival of patients with peritoneal cancer index (PCI) ≤20 undergoing CRS+HIPEC was 27.7 months while a PCI>20 had a median survival of 6.4 months. Thus, PCI>20 is an absolute contraindication for CRS-HIPEC in gastric cancer. Furthermore, PCI was found to predict the ability to achieve CCR-0, and thus survival. Yonemuraet al. (30) determined that the best results are obtained with PCI<6. In another investigation, Chiaet al. (31) also confirmed PCI<6 as a predictor of CCR-0. The estimated median survival for patients with CCR-0, CCR-1 and CCR-2/3 were 43.4 months, 9.5 months and 7.5 months, respectively (29). Glehenet al. (32) did a retrospective multicenter study to evaluate the treatment of CRS combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from gastric cancer. The study found an overall median survival of 9.2 months, while the median survival for completeness of CRS scores of CC-0, CC-1 and CC-2/3 was 15 months, 6 months and 4 months, respectively (Table 4).

    Table 3 Comparison of median survival of CRS+HIPEC versus surgery alone

    Quality of life (QOL)

    Many practitioners argue that QOL after CRS-HIPEC is prohibitive. Tsilimpariset al. investigated QOL after CRSHIPEC (33) and found that pre- and post-operative QOL did not differ statistically with most of the reduced elements recovering after 6–12 months. Zhuet al. (34) in a comprehensive review of QOL after CRS-HIPEC concluded that within 3 months 50% of patients returned to baseline QOL. We agree with other authors that reduced QOL of patients after CRS and HIPEC should not be used as an argument to deny surgical therapy to these patients.

    Conclusions

    Gastric cancer with peritoneal carcinomatosis has long been associated with a poor prognosis and is usually treated with palliative systemic chemotherapy. The state of the art treatment regimen including CRS and HIPEC has shown to increase OS rates. Gillet al. (35) did a systematic review of non-randomized, randomized, and prospective cohort trials regarding the effectiveness of CRS and HIPEC in patients with gastric cancer and peritoneal carcinomatosis and found that the overall median survival was 7.9 (range:6.1–9.2) months and improved to 15 months if the patients had a CCR score of 0 or 1. They also found that the 1-year survival rate was 43% (range: 22%–68%). Although there is a higher perioperative morbidity and mortality associated with CRS and HIPEC, patients should not be dissuaded because it has been found that the postoperative QOL was similar to that of preoperative by 6–12 months (36). Surgeons’ proficiency has a major impact on outcomes in CRS-HIPEC. Rahulet al. (37) reviewed extensively the subject and concluded that the learning curve for a center is approximately 140–220 cases, and for individual surgeons about 33–70 cases. Our recommendations are: CRSHIPEC for gastric cancer should be contemplated in a multidisciplinary manner for physically fit patients [Eastern Cooperative Oncology Group (ECOG) performance status score of 0/1 without significant comorbidities] who underwent staging laparoscopy with PCI<6 and to be performed by experienced surgeons.

    Acknowledgements

    None.

    Footnote

    Conflicts of Interest: The authors have no conflicts of interest to declare.

    1.Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon: IARC, 2013. Available online: http://globocan. iarc.fr/Pages/fact_sheets_population.aspx

    2.Bray F, Ren JS, Masuyer E, et al. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 2013;132:1133-45.

    3.Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.

    4.Edge SB, Byrd DR, Compton CC, et al. AJCC cancer staging manual. 7th edition. New York: Springer, 2010.

    5.Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 2000;88:358-363.

    6.Fanelli MF, de Paiva TF Jr, Silva MJ, et al. Predictors of peritoneal carcinomatosis in patients with gastric cancer treated at a single institution in Brazil. J Surg Oncol 2009;100:452-5.

    7.Tanaka T, Kumagai K, Shimizu K, et al. Peritoneal metastasis in gastric cancer with particular reference to lymphatic advancement; extranodal invasion is a significant risk factor for peritoneal metastasis. J Surg Oncol 2000;75:165-71.

    8.Roviello F, Marrelli D, de Manzoni G, et al. Prospective study of peritoneal recurrence after curative surgery for gastric cancer. Br J Surg 2003; 90:1113-9.

    9.Kim KW, Chow O, Parikh K, et al. Peritoneal carcinomatosis in patients with gastric cancer, and the role for surgical resection, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy. Am J Surg 2014;207:78-83.

    10.Thomassen I, van Gestel YR, van Ramshorst B, et al. Peritoneal carcinomatosis of gastric origin: A population-based study on incidence, survival and risk factors. Int J Cancer 2014;134:622-8.

    11.Bozzetti F, Yu W, Baratti D, et al. Locoregional treatment of peritoneal carcinomatosis from gastric cancer. J Surg Oncol 2008;98:273-6.

    12.Wagner AD, Unverzagt S, Grothe W, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2010;17:Cd004064.

    13.GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group, Oba K, Paoletti X, et al. Role of chemotherapy for advanced/recurrent gastric cancer: an individualpatient-data meta-analysis. Eur J Cancer 2013; 49:1565-77.

    14.Hioki M, Gotohda N, Konishi M, et al. Predictive factors improving survival after gastrectomy in gastric cancer patients with peritoneal carcinomatosis. World J Surg 2010;34:555-62.

    15.Kerkar SP, Kemp CD, Duffy A, et al. The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone. Trials 2009;10:121.

    16.Hultman B, Lundkvist J, Glimelius B, et al. Costs and clinical outcome of neoadjuvant systemic chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from gastric cancer. ActaOncol 2012;51:112-21.

    17.Ikeguchi M, Oka A, Tsujitani S, et al. Relationship between area of serosal invasion and intraperitoneal free cancer cells in patients with gastric cancer. Anticancer Res 1994;14:2131-4.

    18.Kuramoto M, Shimada S, Ikeshima S, et al. Extensive intraoperative peritoneal lavage as a standard prophylactic strategy for peritoneal recurrence in patients with gastric carcinoma. Ann Surg 2009; 250:242-6.

    19.Yang XJ, Huang CQ, Suo T, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol 2011;18:1575-81.

    20.Yonemura Y, de Aretxabala X, Fujimura T, et al. Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomized controlled study. Hepatogastroenterology 2001;48:1776-82.

    21.Fujimura T, Yonemura Y, Muraoka K, et al. Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer: randomized controlled study. World J Surg 1994;18:150-5.

    22.Yu W, Whang I, Chung HY, et al. Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: results of a prospective randomized trial. World J Surg 2001;25:985-90.

    23.Fujimoto S, Takahashi M, Mutou T, et al. Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery. Cancer 1997;79:884-91.

    24.Hirose K, Katayama K, Iida A, et al. Efficacy of continuous hyperthermic peritoneal perfusion for the prophylaxis and treatment of peritoneal metastasis of advanced gastric cancer: evaluation by multivariate regression analysis. Oncology 1999;57:106-14.

    25.Yonemura Y, Kawamura T, Bandou E, et al. Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion. Br J Surg 2005;92:370-5.

    26.Glehen O, Schreiber V, Cotte E, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg 2004;139:20-6.

    27.Hall JJ, Loggie BW, Shen P, et al. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer. J Gastrointest Surg 2004;8:454-63.

    28.Scaringi S, Kianmanesh R, Sabate JM, et al. Advanced gastric cancer with or without peritoneal carcinomatosis treated with hyperthermic intraperitoneal chemotherapy: a single western center experience. Eur J Surg Oncol 2008;34:1246-52.

    29.Yang XJ, Li Y, Yonemura Y. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat gastric cancer with ascites and/or peritoneal carcinomatosis: Results from a Chinese center. J Surg Oncol 2010;101:457-64.

    30.Yonemura Y, Ishibashi H, Hirano M, et al. Effects of neoadjuvant laparoscopic hyperthermic intraperitoneal chemotherapy and neoadjuvant intraperitoneal/systemic chemotherapy on peritoneal metastases from gastric cancer. Ann Surg Oncol 2017;24:478-85.

    31.Chia CS, You B, Decullier E, et al. Patients with peritoneal carcinomatosis from gastric cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is cure a possibility? Ann Surg Oncol 2016;23:1971-9.

    32.Glehen O, Gilly FN, Arvieux C, et al. Peritoneal carcinomatosis from gastric cancer: a multiinstitutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol 2010;17:2370-7.

    33.Tsilimparis N, Bockelmann C, Raue W, et al. Quality of life in patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is it worth the risk? Ann Surg Oncol 2013;20:226-32.

    34.Zhu Y, Hanna N, Boutros C, et al. Assessment of clinical benefit and quality of life in patients undergoing cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) for management of peritoneal metastases. J Gastrointest Oncol 2013;4:62-71.

    35.Gill RS, Al-Adra DP, Nagendran J, et al. Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity. J SurgOncol 2011;104:692-8.

    36.Tsilimparis N, Bockelmann C, Raue W, et al. Quality of life in patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is it worth the risk? Ann Surg Oncol 2013;20:226-32.

    37.Rajeev R, Klooster B, Turaga KK, et al. Impact of surgical volume of centers on post-operative outcomes from cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion. J Gastrointest Oncol 2016;7:122-8.

    Cite this article as: Ellison LM, Man Y, Stojadinovic A, Xin H, Avital I. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in treatment of gastric cancer with peritoneal carcinomatosis. Chin J Cancer Res 2017;29(1):86-92. doi: 10.21147/j.issn.1000-9604.2017.01.10

    10.21147/j.issn.1000-9604.2017.01.10

    Hongwu Xin, MD, PhD. Laboratory of Oncology, Center for Molecular Medicine, Medical School, Yangtze University, Jingzhou 434023, China. Email: hongwu_xin@126.com; Itzhak Avital, MD. CEO, P8Medicine, New Brunswick, NJ 08901, USA. Email: itzhak. avital@gmail.com.

    Submitted Apr 27, 2016. Accepted for publication Dec 28, 2016.

    赤兔流量卡办理| 国产精品电影一区二区三区| 亚洲精品亚洲一区二区| 97人妻精品一区二区三区麻豆| 变态另类成人亚洲欧美熟女| 在线国产一区二区在线| 看免费av毛片| 欧美另类亚洲清纯唯美| 99热这里只有精品一区| 亚洲国产精品久久男人天堂| 观看免费一级毛片| 亚洲av成人精品一区久久| 成人欧美大片| 中文在线观看免费www的网站| 久久精品国产亚洲av天美| 一卡2卡三卡四卡精品乱码亚洲| 久久久国产成人精品二区| 97超级碰碰碰精品色视频在线观看| 日韩有码中文字幕| 久久久国产成人免费| 亚洲av免费高清在线观看| 国产成人影院久久av| 久久性视频一级片| 久久久色成人| 色精品久久人妻99蜜桃| 岛国在线免费视频观看| 老鸭窝网址在线观看| 日韩高清综合在线| 午夜老司机福利剧场| 噜噜噜噜噜久久久久久91| a级毛片a级免费在线| 国产亚洲欧美在线一区二区| 国产精品日韩av在线免费观看| 男女床上黄色一级片免费看| 欧美黑人欧美精品刺激| 亚州av有码| 国产亚洲精品久久久com| 一区二区三区四区激情视频 | 午夜a级毛片| 久久亚洲精品不卡| av欧美777| 少妇丰满av| 久久人人精品亚洲av| 在线观看一区二区三区| 久久精品国产自在天天线| 在线观看一区二区三区| 五月伊人婷婷丁香| www.色视频.com| 免费高清视频大片| 亚洲av电影在线进入| 日本免费a在线| 免费人成视频x8x8入口观看| 给我免费播放毛片高清在线观看| bbb黄色大片| 国产一区二区三区在线臀色熟女| 国产一区二区在线av高清观看| 亚洲熟妇中文字幕五十中出| 午夜两性在线视频| 午夜久久久久精精品| 99热这里只有是精品50| 看片在线看免费视频| 成人国产综合亚洲| 国产精品亚洲一级av第二区| 91久久精品电影网| 亚洲精品亚洲一区二区| 亚洲片人在线观看| 丰满的人妻完整版| 有码 亚洲区| 91在线精品国自产拍蜜月| 午夜老司机福利剧场| 亚洲成人久久爱视频| 亚洲黑人精品在线| 亚洲无线在线观看| 亚洲综合色惰| 九九热线精品视视频播放| 久久久久久久精品吃奶| 欧美黑人巨大hd| 好男人在线观看高清免费视频| 97超级碰碰碰精品色视频在线观看| 欧洲精品卡2卡3卡4卡5卡区| a级一级毛片免费在线观看| 欧美激情久久久久久爽电影| 欧美三级亚洲精品| 99国产极品粉嫩在线观看| 草草在线视频免费看| 精品久久国产蜜桃| 一夜夜www| 国产欧美日韩一区二区精品| 免费看日本二区| 久久久久久久久中文| 婷婷精品国产亚洲av| 久久精品人妻少妇| 3wmmmm亚洲av在线观看| 亚洲自偷自拍三级| 麻豆国产97在线/欧美| 亚洲18禁久久av| 午夜亚洲福利在线播放| 毛片女人毛片| 久久精品国产99精品国产亚洲性色| 最近最新中文字幕大全电影3| 国产午夜精品论理片| 动漫黄色视频在线观看| 国产精品影院久久| 色吧在线观看| 美女xxoo啪啪120秒动态图 | 午夜日韩欧美国产| 一个人看的www免费观看视频| 国产爱豆传媒在线观看| 日本与韩国留学比较| 欧美精品国产亚洲| 欧美激情在线99| 久99久视频精品免费| 99久国产av精品| 天堂网av新在线| 日韩精品中文字幕看吧| 亚洲一区二区三区色噜噜| 男人舔奶头视频| 久久久久久久久久黄片| av视频在线观看入口| 1024手机看黄色片| 丰满人妻熟妇乱又伦精品不卡| 日韩欧美在线乱码| 亚洲精品在线美女| 丁香欧美五月| 哪里可以看免费的av片| 日韩av在线大香蕉| 少妇人妻精品综合一区二区 | 简卡轻食公司| 两人在一起打扑克的视频| 亚洲国产精品久久男人天堂| 成人一区二区视频在线观看| 国产精品99久久久久久久久| 色在线成人网| 在线免费观看的www视频| 超碰av人人做人人爽久久| 最后的刺客免费高清国语| 夜夜夜夜夜久久久久| 最近最新中文字幕大全电影3| 内射极品少妇av片p| 动漫黄色视频在线观看| av天堂在线播放| 久久久久久久久大av| 在线观看美女被高潮喷水网站 | 亚洲人成网站在线播| 国产色婷婷99| 人妻制服诱惑在线中文字幕| av在线蜜桃| 搡女人真爽免费视频火全软件 | 久久久国产成人精品二区| 真实男女啪啪啪动态图| 特级一级黄色大片| 欧美三级亚洲精品| 亚洲美女黄片视频| 免费高清视频大片| 最后的刺客免费高清国语| 欧美黄色淫秽网站| 99热这里只有是精品50| 亚洲最大成人中文| 亚洲精品亚洲一区二区| 高清日韩中文字幕在线| 免费观看人在逋| 国产欧美日韩一区二区精品| 欧美国产日韩亚洲一区| 久久久久久久久久成人| 两个人的视频大全免费| 草草在线视频免费看| 国产精品自产拍在线观看55亚洲| 日韩欧美精品免费久久 | 少妇人妻一区二区三区视频| 哪里可以看免费的av片| 欧美成人一区二区免费高清观看| 51国产日韩欧美| 丰满人妻熟妇乱又伦精品不卡| 久久久久免费精品人妻一区二区| 国产一级毛片七仙女欲春2| 3wmmmm亚洲av在线观看| 最近视频中文字幕2019在线8| 亚洲黑人精品在线| 嫩草影院入口| 嫁个100分男人电影在线观看| 99在线视频只有这里精品首页| 国产淫片久久久久久久久 | 国产白丝娇喘喷水9色精品| 午夜免费成人在线视频| 亚洲精品色激情综合| 久久久久久国产a免费观看| 日韩欧美精品免费久久 | 丁香欧美五月| 综合色av麻豆| 国产美女午夜福利| 亚洲在线观看片| 国产毛片a区久久久久| 中文字幕av成人在线电影| 亚洲av美国av| 男女视频在线观看网站免费| 成熟少妇高潮喷水视频| 亚洲在线观看片| 老熟妇乱子伦视频在线观看| 日韩成人在线观看一区二区三区| 精品久久久久久久久av| 亚洲av免费高清在线观看| 亚洲人成网站高清观看| 国产精品一区二区三区四区免费观看 | 亚洲国产色片| 国产成人啪精品午夜网站| 天天一区二区日本电影三级| 亚洲美女黄片视频| 综合色av麻豆| 简卡轻食公司| 亚洲av成人精品一区久久| 国产老妇女一区| 99久久精品热视频| 观看美女的网站| aaaaa片日本免费| 美女被艹到高潮喷水动态| 国产极品精品免费视频能看的| 美女黄网站色视频| 午夜福利在线观看吧| 国产成人欧美在线观看| 欧美最黄视频在线播放免费| 变态另类成人亚洲欧美熟女| 搡老岳熟女国产| 久久久久久国产a免费观看| av女优亚洲男人天堂| 亚洲天堂国产精品一区在线| 精品福利观看| 日韩中字成人| 观看美女的网站| 色视频www国产| 真人做人爱边吃奶动态| 国内精品美女久久久久久| 日韩欧美一区二区三区在线观看| 99久久无色码亚洲精品果冻| 国产精品伦人一区二区| 久久久久久久久中文| 日韩人妻高清精品专区| 变态另类丝袜制服| 国产亚洲精品久久久com| 久久国产精品人妻蜜桃| 免费无遮挡裸体视频| 精品国产三级普通话版| 亚洲国产精品成人综合色| 欧美高清性xxxxhd video| 亚洲av五月六月丁香网| 日韩 亚洲 欧美在线| 极品教师在线视频| 亚洲成av人片在线播放无| 日韩欧美国产一区二区入口| 噜噜噜噜噜久久久久久91| 99热这里只有是精品在线观看 | 亚洲av美国av| 午夜免费激情av| 国产色婷婷99| 一个人看的www免费观看视频| 精品久久久久久久久亚洲 | 女人十人毛片免费观看3o分钟| 免费在线观看成人毛片| av专区在线播放| 国产视频一区二区在线看| 国产一区二区在线观看日韩| 亚洲av第一区精品v没综合| 久久久国产成人精品二区| 亚洲中文日韩欧美视频| 人人妻,人人澡人人爽秒播| 欧美日韩中文字幕国产精品一区二区三区| 最近在线观看免费完整版| 看免费av毛片| 精品人妻偷拍中文字幕| 国产黄a三级三级三级人| 国产真实乱freesex| 老司机福利观看| 激情在线观看视频在线高清| av欧美777| 欧美激情在线99| 高清在线国产一区| 伦理电影大哥的女人| 国产一区二区在线观看日韩| 偷拍熟女少妇极品色| 99精品久久久久人妻精品| 人人妻人人看人人澡| 国产乱人视频| 中文字幕熟女人妻在线| 成年免费大片在线观看| 好看av亚洲va欧美ⅴa在| 国产精品久久久久久亚洲av鲁大| 变态另类丝袜制服| 国产淫片久久久久久久久 | 变态另类成人亚洲欧美熟女| 最新中文字幕久久久久| 欧美黑人巨大hd| 久久久久精品国产欧美久久久| 国产视频一区二区在线看| 亚洲精品色激情综合| 日韩有码中文字幕| 看黄色毛片网站| 人人妻,人人澡人人爽秒播| 午夜福利免费观看在线| 久99久视频精品免费| 日韩欧美在线乱码| 色在线成人网| 天美传媒精品一区二区| 校园春色视频在线观看| 亚洲av二区三区四区| 高清日韩中文字幕在线| 亚洲成av人片免费观看| 免费人成在线观看视频色| 日韩人妻高清精品专区| 亚洲av一区综合| 校园春色视频在线观看| 一个人看的www免费观看视频| 精品国产三级普通话版| 99国产精品一区二区蜜桃av| 久久精品国产亚洲av天美| 日本黄色视频三级网站网址| 免费电影在线观看免费观看| 午夜福利视频1000在线观看| 丁香六月欧美| 神马国产精品三级电影在线观看| or卡值多少钱| 中文字幕精品亚洲无线码一区| 亚洲午夜理论影院| 美女免费视频网站| 亚洲欧美日韩卡通动漫| 欧美色欧美亚洲另类二区| 国产黄片美女视频| 国产精品,欧美在线| 欧美成人一区二区免费高清观看| 窝窝影院91人妻| 我的老师免费观看完整版| 国产精品日韩av在线免费观看| 亚洲人成伊人成综合网2020| 日本熟妇午夜| 99久久精品热视频| 别揉我奶头~嗯~啊~动态视频| netflix在线观看网站| 欧美在线黄色| a在线观看视频网站| 国产在线男女| 国产真实伦视频高清在线观看 | 免费观看人在逋| 欧美极品一区二区三区四区| 久久精品91蜜桃| 一进一出好大好爽视频| 熟女人妻精品中文字幕| 国产精品亚洲美女久久久| 午夜a级毛片| 好男人在线观看高清免费视频| 国产成+人综合+亚洲专区| 草草在线视频免费看| 国产亚洲av嫩草精品影院| 9191精品国产免费久久| 少妇被粗大猛烈的视频| 精品欧美国产一区二区三| 亚洲无线观看免费| 九九久久精品国产亚洲av麻豆| 亚洲成av人片免费观看| 搡老熟女国产l中国老女人| 99久久精品热视频| 51国产日韩欧美| 成人高潮视频无遮挡免费网站| 88av欧美| 日本黄色片子视频| 三级男女做爰猛烈吃奶摸视频| 国产国拍精品亚洲av在线观看| 性欧美人与动物交配| 亚洲电影在线观看av| 有码 亚洲区| 国产精品伦人一区二区| 色哟哟哟哟哟哟| 日日干狠狠操夜夜爽| 天堂网av新在线| 久久国产乱子伦精品免费另类| 欧美zozozo另类| 久久人妻av系列| 亚洲真实伦在线观看| 精品久久久久久久末码| 国产欧美日韩精品一区二区| 久久精品国产自在天天线| 麻豆国产av国片精品| 国产69精品久久久久777片| 99久久九九国产精品国产免费| 久久久成人免费电影| 成年免费大片在线观看| 亚洲成人免费电影在线观看| 欧美性感艳星| 亚洲天堂国产精品一区在线| 亚洲真实伦在线观看| 国产一区二区三区在线臀色熟女| 亚洲国产精品久久男人天堂| 精品人妻偷拍中文字幕| 啪啪无遮挡十八禁网站| 精品国内亚洲2022精品成人| 一a级毛片在线观看| 亚洲成人久久爱视频| 国产精品1区2区在线观看.| 欧美一区二区国产精品久久精品| 人妻久久中文字幕网| 老熟妇仑乱视频hdxx| 色播亚洲综合网| 赤兔流量卡办理| 五月玫瑰六月丁香| www.熟女人妻精品国产| 亚洲乱码一区二区免费版| 最近在线观看免费完整版| 亚洲经典国产精华液单 | 久久久精品大字幕| 精品一区二区三区视频在线观看免费| 90打野战视频偷拍视频| 国产精品久久电影中文字幕| 欧美一区二区精品小视频在线| 色播亚洲综合网| 国产激情偷乱视频一区二区| 亚洲美女视频黄频| 97超级碰碰碰精品色视频在线观看| 全区人妻精品视频| 日韩欧美免费精品| 又黄又爽又刺激的免费视频.| 日韩欧美国产一区二区入口| 亚洲欧美清纯卡通| 不卡视频在线观看欧美| 亚洲最大成人av| 国产成人精品一,二区| 少妇被粗大猛烈的视频| 水蜜桃什么品种好| 三级男女做爰猛烈吃奶摸视频| 久久影院123| 精品视频人人做人人爽| 亚洲av成人精品一二三区| 少妇人妻精品综合一区二区| 成人亚洲精品一区在线观看 | 26uuu在线亚洲综合色| 少妇熟女欧美另类| 肉色欧美久久久久久久蜜桃 | 亚洲欧美日韩东京热| 成人特级av手机在线观看| 亚洲人成网站高清观看| 又大又黄又爽视频免费| 免费在线观看成人毛片| 国产女主播在线喷水免费视频网站| 一区二区三区乱码不卡18| 免费大片黄手机在线观看| 嫩草影院精品99| 国产亚洲av片在线观看秒播厂| 日韩伦理黄色片| 在线免费观看不下载黄p国产| 成人亚洲欧美一区二区av| 美女xxoo啪啪120秒动态图| 日韩电影二区| 亚洲精品亚洲一区二区| 在线观看国产h片| 亚洲在线观看片| 男的添女的下面高潮视频| 黄色怎么调成土黄色| 人妻 亚洲 视频| 日韩三级伦理在线观看| 99热这里只有精品一区| 午夜福利在线在线| 人妻少妇偷人精品九色| .国产精品久久| 国产精品精品国产色婷婷| 免费人成在线观看视频色| 99久久中文字幕三级久久日本| 久久99热这里只频精品6学生| 国产久久久一区二区三区| 在线观看av片永久免费下载| 最近手机中文字幕大全| 精品酒店卫生间| 黄色怎么调成土黄色| 欧美+日韩+精品| 一级毛片电影观看| 美女高潮的动态| 你懂的网址亚洲精品在线观看| 99九九线精品视频在线观看视频| 中文字幕久久专区| av免费在线看不卡| 国产爽快片一区二区三区| 久久国产乱子免费精品| av女优亚洲男人天堂| 亚洲av日韩在线播放| 久久久色成人| 熟女电影av网| 成人无遮挡网站| 天天一区二区日本电影三级| av一本久久久久| 精品久久久久久久人妻蜜臀av| 久久人人爽人人爽人人片va| 观看免费一级毛片| 免费av毛片视频| 国产爽快片一区二区三区| 日本色播在线视频| 超碰97精品在线观看| 只有这里有精品99| 少妇 在线观看| 天天躁夜夜躁狠狠久久av| 99久国产av精品国产电影| 夜夜看夜夜爽夜夜摸| 午夜老司机福利剧场| 成人亚洲精品一区在线观看 | 国产真实伦视频高清在线观看| 午夜激情福利司机影院| 久久热精品热| 亚洲欧美中文字幕日韩二区| 免费观看在线日韩| 最后的刺客免费高清国语| 欧美最新免费一区二区三区| 免费观看无遮挡的男女| 天天一区二区日本电影三级| 欧美性感艳星| 亚洲国产精品999| 久久久精品欧美日韩精品| 久久久精品免费免费高清| 爱豆传媒免费全集在线观看| 乱码一卡2卡4卡精品| 国产伦精品一区二区三区视频9| 欧美极品一区二区三区四区| 看非洲黑人一级黄片| 晚上一个人看的免费电影| 街头女战士在线观看网站| 久久久久性生活片| 日本与韩国留学比较| 热re99久久精品国产66热6| 久久99蜜桃精品久久| 免费看日本二区| 最新中文字幕久久久久| 亚洲人成网站在线播| 在线观看一区二区三区| 99热这里只有精品一区| 亚洲精品成人久久久久久| 亚洲成人一二三区av| 精品人妻视频免费看| 男人狂女人下面高潮的视频| 深夜a级毛片| 建设人人有责人人尽责人人享有的 | 免费大片黄手机在线观看| 视频中文字幕在线观看| 免费看光身美女| 91久久精品国产一区二区成人| 久久鲁丝午夜福利片| 嫩草影院入口| 老司机影院毛片| 一二三四中文在线观看免费高清| 黄色配什么色好看| 国产免费视频播放在线视频| 在线a可以看的网站| 国产亚洲av嫩草精品影院| 成人毛片60女人毛片免费| 一本一本综合久久| 美女脱内裤让男人舔精品视频| 性色avwww在线观看| av.在线天堂| 热99国产精品久久久久久7| 亚洲精品aⅴ在线观看| 亚洲欧美一区二区三区国产| 亚洲精品亚洲一区二区| 青春草国产在线视频| 91aial.com中文字幕在线观看| 欧美日韩亚洲高清精品| 国内揄拍国产精品人妻在线| 涩涩av久久男人的天堂| 精品午夜福利在线看| 精品久久久噜噜| 日本猛色少妇xxxxx猛交久久| 午夜免费男女啪啪视频观看| 听说在线观看完整版免费高清| 国产精品99久久久久久久久| 视频中文字幕在线观看| 黄色配什么色好看| 久久午夜福利片| 国产精品久久久久久久电影| 久久久色成人| 亚洲精品自拍成人| 建设人人有责人人尽责人人享有的 | 一级黄片播放器| 亚洲自拍偷在线| 午夜精品国产一区二区电影 | 校园人妻丝袜中文字幕| 五月开心婷婷网| 最后的刺客免费高清国语| 永久网站在线| 黄色视频在线播放观看不卡| 亚洲av国产av综合av卡| 国产精品久久久久久久久免| 日韩制服骚丝袜av| 丝袜喷水一区| 国产精品人妻久久久影院| 99久久精品一区二区三区| 国产亚洲最大av| 搞女人的毛片| 大片免费播放器 马上看| 亚洲欧美精品自产自拍| 狂野欧美激情性bbbbbb| 亚洲欧美日韩无卡精品| 极品教师在线视频| 国产精品久久久久久精品电影| 亚洲三级黄色毛片| 一级毛片久久久久久久久女| 国产精品一区二区三区四区免费观看| 久久综合国产亚洲精品| 九草在线视频观看| 欧美成人一区二区免费高清观看| 成年女人看的毛片在线观看| 乱系列少妇在线播放| 亚洲欧美精品专区久久| 亚洲精品乱码久久久v下载方式| 日韩制服骚丝袜av| 精品一区二区三卡| 深爱激情五月婷婷| 九草在线视频观看| 日本一二三区视频观看| 亚洲精品乱码久久久久久按摩| 国产精品国产三级国产专区5o| 日本午夜av视频| 国产亚洲av片在线观看秒播厂| 精品久久久久久久久av| 人妻一区二区av|